[Form 4] Shattuck Labs, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Shattuck Labs insider purchase reported. The company's Chief Technical Officer, Abhinav A. Shukla, acquired 5,122 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025 at a combined purchase price of $0.8677 per share with accompanying warrant. The filing also notes Shukla beneficially owns 81,258 shares after the transaction, which includes 600 shares purchased via the 2020 Employee Stock Purchase Plan on February 15, 2025 and 2,000 shares under the ESPP on August 15, 2025. The warrants cover 5,122 shares exercisable upon public disclosure of Phase 1 clinical trial data and planned Phase 2 design.

Positive

• Insider purchase by the Chief Technical Officer of 5,122 shares plus warrants at $0.8677 per unit
• Post-transaction beneficial ownership of 81,258 shares, including recent ESPP purchases

Negative

• None.

Insights

Securities Analyst

TL;DR: Company CTO participated in a private placement, adding equity and warrants; this shows management financial participation but not material on its own.

The reporting shows an insider purchase of 5,122 common shares with attached warrants at $0.8677 per unit in a private placement that closed 08/25/2025. Post-transaction beneficial ownership is 81,258 shares including recent ESPP purchases. The warrant exercise is tied to public disclosure of Phase 1 data and Phase 2 design, linking option exercisability to clinical milestones rather than fixed dates. For investors, this is a direct signal of insider participation but the filing does not disclose relative stake percentage or total outstanding shares, limiting assessment of materiality.

Corporate Governance Expert

TL;DR: Insider acquisition follows a disclosed securities purchase agreement; warrants include milestone-based exercisability tied to clinical data releases.

The Form 4 documents a securities purchase agreement executed 08/04/2025 and closed 08/25/2025 with accredited investors including the CTO. The warrants' exercisability depends on public announcements about Phase 1 trial data and Phase 2 design, which creates a conditional vesting-like feature from a governance standpoint. The report is properly executed via attorney-in-fact signature dated 08/27/2025. No departures, grants of discretionary equity, or dispositions are reported besides the private placement and ESPP inclusions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shukla Abhinav A.

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A(1)		5,122	A	$0.8677(1)	81,258(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$1.0846	08/25/2025		A(1)		5,122		(3)	(3)	Common Stock	5,122	(1)	5,122	D

Explanation of Responses:

1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

2. Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on February 15, 2025 and 2,000 shares acquired by the Reporting Person under the ESPP on August 15, 2025.

3. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

	/s/ Andrew R. Neill, Attorney-in-fact for Abhinav A. Shukla	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Abhinav A. Shukla file on Form 4 for STTK?

The filing reports Shukla acquired 5,122 common shares and accompanying warrants in a private placement that closed on August 25, 2025 at a combined price of $0.8677 per share with warrant.

How many shares does Shukla beneficially own after the transaction?

The Form 4 states Shukla beneficially owns 81,258 shares following the reported transaction.

Are there any warrants included and when are they exercisable?

Yes. Warrants covering 5,122 shares were issued. They are exercisable from issuance until 30 days after public disclosure of Phase 1 SL-325 single and multiple ascending dose data and the planned Phase 2 design.

Was this transaction part of a securities purchase agreement?

Yes. The Issuer entered into a securities purchase agreement on August 4, 2025 and the private placement closed on August 25, 2025 with accredited investors including the reporting person.

Does the Form 4 disclose any sales or dispositions by the reporting person?

No. The Form 4 reports an acquisition (A) of shares and warrants; no dispositions are reported.